CLINICAL TRIALS PROFILE FOR MOUNJARO
✉ Email this page to a colleague
All Clinical Trials for MOUNJARO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05708859 ↗ | Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Not yet recruiting | Eli Lilly and Company | Phase 4 | 2023-02-01 | A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis. |
| NCT05708859 ↗ | Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Not yet recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 4 | 2023-02-01 | A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis. |
| NCT06073184 ↗ | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium | Not yet recruiting | University Health Network, Toronto | Phase 2 | 2024-09-01 | The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes. |
| NCT06162715 ↗ | GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial | Not yet recruiting | Vanderbilt University Medical Center | Phase 2 | 2024-10-01 | The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MOUNJARO
Condition Name
Clinical Trial Locations for MOUNJARO
Trials by Country
Clinical Trial Progress for MOUNJARO
Clinical Trial Phase
Clinical Trial Sponsors for MOUNJARO
Sponsor Name
